$SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Healthcare
Sector
Biotechnology
Industry
David A. Happel
CEO
14
Employees
$5.21
Current Price
$159.66M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $105,463.28 | 19,675 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $105,463.28 | 19,675 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | Happel David Director | Sale | 12,101 | $5.36 | $64,864.99 | View Details |
| Feb 10, 2026 | Chauche Thierry Chief Financial Officer | Sale | 1,312 | $5.36 | $7,032.71 | View Details |
| Feb 10, 2026 | Martins Eduardo Bruno Chief Medical Officer | Sale | 3,640 | $5.36 | $19,511.13 | View Details |
| Feb 10, 2026 | Rozek Elizabeth Chief Legal & Admin. Officer | Sale | 2,622 | $5.36 | $14,054.44 | View Details |
4 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.43
Actual-$0.29
Beat
Revenue
EstimatedN/A
ActualN/A